JP Morgan Chase
NWBO

JP Morgan Chase’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

JP Morgan Chase’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-1,726
Closed -$1K – 5343
2016
Q3 		$1K Sell
1,726
-8
-0.5% -$4 ﹤0.01% 4502
2016
Q2 		$1K Buy
+1,734
New +$1.85K ﹤0.01% 4742
2016
Q1 		– Sell
-1,683
Closed -$5K – 5287
2015
Q4 		$5K Buy
+1,683
New +$8.09K ﹤0.01% 4377
2015
Q2 		– Sell
-38,630
Closed -$285K – 4388
2015
Q1 		$285K Buy
+38,630
New +$260K ﹤0.01% 3725
2014
Q2 		– Sell
-39,199
Closed -$284K – 3776
2014
Q1 		$284K Buy
+39,199
New +$232K ﹤0.01% 3312

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CDH
Charles D. Hyman $1.79B AUM 17.18% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BW
Biegel & Waller Columbia, Maryland $179M AUM 1.6% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $9.79B AUM 20.6% 1-Year Est. Return

JP Morgan Chase's NWBO Position: Q4 2016 in Review

JP Morgan Chase sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 1,726 shares — an estimated $1K sold.

JP Morgan Chase first reported a position in NWBO in Q1 2014 and held it in 5 quarters. The position peaked at $285K in Q1 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • JP Morgan Chase reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • JP Morgan Chase sold 1,726 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $1K.
  • JP Morgan Chase first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q1 2014 and held it in 5 quarters.
  • JP Morgan Chase's Northwest Biotherapeutics, Inc. Common stock position peaked at $285K in Q1 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on JP Morgan Chase's 13F filing for Q4 2016, filed 6 Feb 2017.